- Home
- GMAB vs H Comparison
GMAB vs H Comparison
Compare GMAB & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- H
- Stock Information
- Founded
- GMAB 1999
- H 1957
- Country
- GMAB Denmark
- H United States
- Employees
- GMAB N/A
- H N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- H Hotels/Resorts
- Sector
- GMAB Health Care
- H Consumer Discretionary
- Exchange
- GMAB Nasdaq
- H Nasdaq
- Market Cap
- GMAB 12.8B
- H 12.1B
- IPO Year
- GMAB N/A
- H 2009
- Fundamental
- Price
- GMAB $19.88
- H $135.19
- Analyst Decision
- GMAB Buy
- H Buy
- Analyst Count
- GMAB 9
- H 17
- Target Price
- GMAB $39.17
- H $150.94
- AVG Volume (30 Days)
- GMAB 1.5M
- H 1.1M
- Earning Date
- GMAB 05-08-2025
- H 05-01-2025
- Dividend Yield
- GMAB N/A
- H 0.44%
- EPS Growth
- GMAB 85.27
- H 23.10
- EPS
- GMAB 17.68
- H 7.89
- Revenue
- GMAB $3,135,137,804.00
- H $3,216,000,000.00
- Revenue This Year
- GMAB $17.69
- H $113.53
- Revenue Next Year
- GMAB $14.81
- H $5.73
- P/E Ratio
- GMAB $1.12
- H $17.15
- Revenue Growth
- GMAB 51.92
- H N/A
- 52 Week Low
- GMAB $17.24
- H $102.43
- 52 Week High
- GMAB $30.41
- H $168.20
- Technical
- Relative Strength Index (RSI)
- GMAB 48.84
- H 68.60
- Support Level
- GMAB $18.89
- H $120.36
- Resistance Level
- GMAB $19.67
- H $139.34
- Average True Range (ATR)
- GMAB 0.49
- H 3.44
- MACD
- GMAB -0.12
- H 2.24
- Stochastic Oscillator
- GMAB 34.61
- H 86.66
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.